{"id":194327,"date":"2026-08-10T15:47:09","date_gmt":"2026-08-10T10:17:09","guid":{"rendered":"https:\/\/univest.in\/blogs-2\/?p=194327"},"modified":"2026-08-10T15:47:10","modified_gmt":"2026-08-10T10:17:10","slug":"pros-cons-investing-gland-share","status":"publish","type":"post","link":"https:\/\/univest.in\/blogs-2\/pros-cons-investing-gland-share\/","title":{"rendered":"Gland Pharma Share: Pros and Cons Every Investor Must Know in 2026"},"content":{"rendered":"<div class=\"meta-block\"><\/div>\n<p style=\"border-left: 4px solid #1F4E79; background: #EBF3FB; padding: 10px 16px; font-style: italic;\"><em>Gland Pharma share CMP approx Rs 2,050. 52-week high Rs 2,800, low Rs 1,600. Market Cap Rs 33,500 Cr. P\/E ratio 58.39x.<\/em><\/p>\n<div style=\"background: #F0F7FF; border-left: 4px solid #1F4E79; border-radius: 6px; padding: 14px 18px; margin: 18px 0;\">\n<p style=\"margin: 0 0 8px 0; font-weight: bold; color: #1f4e79;\">Quick Answer<\/p>\n<ul style=\"margin: 0; padding-left: 20px; color: #333;\">\n<li>Gland Pharma share at 58.39x PE \u2014 injectable pharma premium with ROE of 12.67% below quality benchmark<\/li>\n<li>India&#8217;s largest injectable-focused pharmaceutical company: vials, prefilled syringes, lyophilised products<\/li>\n<li>Key concern: Chinese parent Fosun Pharma holds 51% stake \u2014 geopolitical risk for US market injectables<\/li>\n<\/ul>\n<\/div>\n<p>Is the Gland Pharma share a good investment in 2026? This article provides a data-driven analysis of Gland Pharma share pros and cons \u2014 covering business strengths, valuation, growth drivers, and key risks \u2014 based on live data from 7 August 2026.<\/p>\n<p style=\"margin-top: 24px;\"><a href=\"https:\/\/univest.in\/user\/log-in?utm_source=blogs&amp;utm_medium=gland-pharma-pros-cons\"><strong>Click Here \u2014 Get Free Investment Predictions<\/strong><\/a><\/p>\n<div id=\"ez-toc-container\" class=\"ez-toc-v2_0_65 counter-hierarchy ez-toc-counter ez-toc-grey ez-toc-container-direction\">\n<div class=\"ez-toc-title-container\">\n<p class=\"ez-toc-title \" >Table of Contents<\/p>\n<span class=\"ez-toc-title-toggle\"><a href=\"#\" class=\"ez-toc-pull-right ez-toc-btn ez-toc-btn-xs ez-toc-btn-default ez-toc-toggle\" aria-label=\"Toggle Table of Content\"><span class=\"ez-toc-js-icon-con\"><span class=\"\"><span class=\"eztoc-hide\" style=\"display:none;\">Toggle<\/span><span class=\"ez-toc-icon-toggle-span\"><svg style=\"fill: #999;color:#999\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\" class=\"list-377408\" width=\"20px\" height=\"20px\" viewBox=\"0 0 24 24\" fill=\"none\"><path d=\"M6 6H4v2h2V6zm14 0H8v2h12V6zM4 11h2v2H4v-2zm16 0H8v2h12v-2zM4 16h2v2H4v-2zm16 0H8v2h12v-2z\" fill=\"currentColor\"><\/path><\/svg><svg style=\"fill: #999;color:#999\" class=\"arrow-unsorted-368013\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\" width=\"10px\" height=\"10px\" viewBox=\"0 0 24 24\" version=\"1.2\" baseProfile=\"tiny\"><path d=\"M18.2 9.3l-6.2-6.3-6.2 6.3c-.2.2-.3.4-.3.7s.1.5.3.7c.2.2.4.3.7.3h11c.3 0 .5-.1.7-.3.2-.2.3-.5.3-.7s-.1-.5-.3-.7zM5.8 14.7l6.2 6.3 6.2-6.3c.2-.2.3-.5.3-.7s-.1-.5-.3-.7c-.2-.2-.4-.3-.7-.3h-11c-.3 0-.5.1-.7.3-.2.2-.3.5-.3.7s.1.5.3.7z\"\/><\/svg><\/span><\/span><\/span><\/a><\/span><\/div>\n<nav><ul class='ez-toc-list ez-toc-list-level-1 ' ><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-1\" href=\"https:\/\/univest.in\/blogs-2\/pros-cons-investing-gland-share\/#About_Gland_Pharma\" title=\"About Gland Pharma\">About Gland Pharma<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-2\" href=\"https:\/\/univest.in\/blogs-2\/pros-cons-investing-gland-share\/#Key_Financial_Snapshot_Gland_Pharma_Share\" title=\"Key Financial Snapshot: Gland Pharma Share\">Key Financial Snapshot: Gland Pharma Share<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-3\" href=\"https:\/\/univest.in\/blogs-2\/pros-cons-investing-gland-share\/#Top_5_Pros_of_Gland_Pharma_Share\" title=\"Top 5 Pros of Gland Pharma Share\">Top 5 Pros of Gland Pharma Share<\/a><ul class='ez-toc-list-level-3' ><li class='ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-4\" href=\"https:\/\/univest.in\/blogs-2\/pros-cons-investing-gland-share\/#1_Indias_Largest_Injectable_Pharmaceutical_Manufacturer_%E2%80%94_Sterile_Manufacturing_Moat\" title=\"1. India&#8217;s Largest Injectable Pharmaceutical Manufacturer \u2014 Sterile Manufacturing Moat\">1. India&#8217;s Largest Injectable Pharmaceutical Manufacturer \u2014 Sterile Manufacturing Moat<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-5\" href=\"https:\/\/univest.in\/blogs-2\/pros-cons-investing-gland-share\/#2_Complex_Injectable_Portfolio_%E2%80%94_Prefilled_Syringes_Lyophilised_Products_High-Value_Injectables\" title=\"2. Complex Injectable Portfolio \u2014 Prefilled Syringes, Lyophilised Products, High-Value Injectables\">2. Complex Injectable Portfolio \u2014 Prefilled Syringes, Lyophilised Products, High-Value Injectables<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-6\" href=\"https:\/\/univest.in\/blogs-2\/pros-cons-investing-gland-share\/#3_US_European_and_Australian_Market_Access_%E2%80%94_FDA_and_EMA_Approved_Facilities\" title=\"3. US, European, and Australian Market Access \u2014 FDA and EMA Approved Facilities\">3. US, European, and Australian Market Access \u2014 FDA and EMA Approved Facilities<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-7\" href=\"https:\/\/univest.in\/blogs-2\/pros-cons-investing-gland-share\/#4_CDMO_Business_Growth_%E2%80%94_Global_Pharma_Outsourcing_Injectable_Manufacturing\" title=\"4. CDMO Business Growth \u2014 Global Pharma Outsourcing Injectable Manufacturing\">4. CDMO Business Growth \u2014 Global Pharma Outsourcing Injectable Manufacturing<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-8\" href=\"https:\/\/univest.in\/blogs-2\/pros-cons-investing-gland-share\/#5_Complex_Sterile_Manufacturing_Scale_%E2%80%94_300-Plus_ANDA_Pipeline_in_US\" title=\"5. Complex Sterile Manufacturing Scale \u2014 300-Plus ANDA Pipeline in US\">5. Complex Sterile Manufacturing Scale \u2014 300-Plus ANDA Pipeline in US<\/a><\/li><\/ul><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-9\" href=\"https:\/\/univest.in\/blogs-2\/pros-cons-investing-gland-share\/#Key_Cons_of_Gland_Pharma_Share\" title=\"Key Cons of Gland Pharma Share\">Key Cons of Gland Pharma Share<\/a><ul class='ez-toc-list-level-3' ><li class='ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-10\" href=\"https:\/\/univest.in\/blogs-2\/pros-cons-investing-gland-share\/#1_ROE_of_1267_Percent_Below_Injectable_Pharma_Quality_Benchmark\" title=\"1. ROE of 12.67 Percent Below Injectable Pharma Quality Benchmark\">1. ROE of 12.67 Percent Below Injectable Pharma Quality Benchmark<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-11\" href=\"https:\/\/univest.in\/blogs-2\/pros-cons-investing-gland-share\/#2_Chinese_Parent_Fosun_Pharma_51_Percent_Stake_%E2%80%94_US_Market_Geopolitical_Risk\" title=\"2. Chinese Parent Fosun Pharma 51 Percent Stake \u2014 US Market Geopolitical Risk\">2. Chinese Parent Fosun Pharma 51 Percent Stake \u2014 US Market Geopolitical Risk<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-12\" href=\"https:\/\/univest.in\/blogs-2\/pros-cons-investing-gland-share\/#3_US_Generic_Injectable_Price_Erosion_%E2%80%94_Competition_From_Indian_and_Chinese_Generic_Makers\" title=\"3. US Generic Injectable Price Erosion \u2014 Competition From Indian and Chinese Generic Makers\">3. US Generic Injectable Price Erosion \u2014 Competition From Indian and Chinese Generic Makers<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-13\" href=\"https:\/\/univest.in\/blogs-2\/pros-cons-investing-gland-share\/#4_PE_of_5839x_Expensive_for_Current_ROE_%E2%80%94_Requires_Complex_Product_Mix_Shift_to_Justify\" title=\"4. PE of 58.39x Expensive for Current ROE \u2014 Requires Complex Product Mix Shift to Justify\">4. PE of 58.39x Expensive for Current ROE \u2014 Requires Complex Product Mix Shift to Justify<\/a><\/li><\/ul><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-14\" href=\"https:\/\/univest.in\/blogs-2\/pros-cons-investing-gland-share\/#Is_Gland_Pharma_Share_a_Good_Investment_in_2026\" title=\"Is Gland Pharma Share a Good Investment in 2026?\">Is Gland Pharma Share a Good Investment in 2026?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-15\" href=\"https:\/\/univest.in\/blogs-2\/pros-cons-investing-gland-share\/#Key_Risks_Before_Buying_Gland_Pharma_Share\" title=\"Key Risks Before Buying Gland Pharma Share\">Key Risks Before Buying Gland Pharma Share<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-16\" href=\"https:\/\/univest.in\/blogs-2\/pros-cons-investing-gland-share\/#Conclusion\" title=\"Conclusion\">Conclusion<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-17\" href=\"https:\/\/univest.in\/blogs-2\/pros-cons-investing-gland-share\/#Frequently_Asked_Questions_%E2%80%94_Gland_Pharma_Share\" title=\"Frequently Asked Questions \u2014 Gland Pharma Share\">Frequently Asked Questions \u2014 Gland Pharma Share<\/a><ul class='ez-toc-list-level-3' ><li class='ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-18\" href=\"https:\/\/univest.in\/blogs-2\/pros-cons-investing-gland-share\/#What_are_the_main_pros_of_Gland_Pharma_share\" title=\"What are the main pros of Gland Pharma share?\">What are the main pros of Gland Pharma share?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-19\" href=\"https:\/\/univest.in\/blogs-2\/pros-cons-investing-gland-share\/#What_are_the_risks\" title=\"What are the risks?\">What are the risks?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-20\" href=\"https:\/\/univest.in\/blogs-2\/pros-cons-investing-gland-share\/#Is_Gland_Pharma_share_a_good_investment\" title=\"Is Gland Pharma share a good investment?\">Is Gland Pharma share a good investment?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-21\" href=\"https:\/\/univest.in\/blogs-2\/pros-cons-investing-gland-share\/#What_is_the_52-week_range\" title=\"What is the 52-week range?\">What is the 52-week range?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-22\" href=\"https:\/\/univest.in\/blogs-2\/pros-cons-investing-gland-share\/#What_are_sterile_injectables_and_why_is_manufacturing_them_difficult\" title=\"What are sterile injectables and why is manufacturing them difficult?\">What are sterile injectables and why is manufacturing them difficult?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-23\" href=\"https:\/\/univest.in\/blogs-2\/pros-cons-investing-gland-share\/#What_is_Fosun_Pharmas_ownership_of_Gland_Pharma\" title=\"What is Fosun Pharma&#8217;s ownership of Gland Pharma?\">What is Fosun Pharma&#8217;s ownership of Gland Pharma?<\/a><\/li><\/ul><\/li><\/ul><\/nav><\/div>\n<h2><span class=\"ez-toc-section\" id=\"About_Gland_Pharma\"><\/span><strong>About Gland Pharma<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p>Gland Pharma Limited (NSE: GLAND) is a Hyderabad-based injectable pharmaceutical company founded in 1978, majority-owned by Fosun Pharma (China, 51 percent). India&#8217;s largest injectable pharma company, it manufactures and exports complex sterile injectables \u2014 vials, prefilled syringes, ampoules, and lyophilised (freeze-dried) products \u2014 to the US, Europe, Canada, and Australia. Gland is a specialty CDMO-like injectable company with a complex sterile manufacturing advantage.<\/p>\n<h2><span class=\"ez-toc-section\" id=\"Key_Financial_Snapshot_Gland_Pharma_Share\"><\/span><strong>Key Financial Snapshot: Gland Pharma Share<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<table>\n<thead>\n<tr>\n<th>Parameter<\/th>\n<th>Details<\/th>\n<\/tr>\n<\/thead>\n<tbody>\n<tr>\n<td>Company<\/td>\n<td><a href=\"https:\/\/univest.in\/stocks\/gland\/gland-pharma-ltd-share-price-today\">Gland Pharma<\/a><\/td>\n<\/tr>\n<tr>\n<td>NSE Symbol<\/td>\n<td>GLAND<\/td>\n<\/tr>\n<tr>\n<td>Sector<\/td>\n<td>Injectable Pharma CDMO<\/td>\n<\/tr>\n<tr>\n<td>CMP (Approx)<\/td>\n<td>Rs 2,050<\/td>\n<\/tr>\n<tr>\n<td>52-Week High<\/td>\n<td>Rs 2,800<\/td>\n<\/tr>\n<tr>\n<td>52-Week Low<\/td>\n<td>Rs 1,600<\/td>\n<\/tr>\n<tr>\n<td>Market Cap<\/td>\n<td>Rs 33,500 Cr<\/td>\n<\/tr>\n<tr>\n<td>P\/E Ratio<\/td>\n<td>58.39x<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<p><em>Data approximate. Verify at <a href=\"https:\/\/www.nseindia.com\" rel=\"nofollow noopener\" target=\"_blank\">nseindia.com<\/a>.<\/em><\/p>\n<h2><span class=\"ez-toc-section\" id=\"Top_5_Pros_of_Gland_Pharma_Share\"><\/span><strong>Top 5 Pros of Gland Pharma Share<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<h3><span class=\"ez-toc-section\" id=\"1_Indias_Largest_Injectable_Pharmaceutical_Manufacturer_%E2%80%94_Sterile_Manufacturing_Moat\"><\/span><strong>1. India&#8217;s Largest Injectable Pharmaceutical Manufacturer \u2014 Sterile Manufacturing Moat<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p>Gland Pharma share represents India&#8217;s dominant sterile injectable pharmaceutical company \u2014 with the broadest regulatory-approved complex sterile manufacturing capacity in India. Sterile injectable manufacturing requires FDA-approved facilities, strict aseptic manufacturing protocols, and continuous regulatory compliance that creates a very high entry barrier.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"2_Complex_Injectable_Portfolio_%E2%80%94_Prefilled_Syringes_Lyophilised_Products_High-Value_Injectables\"><\/span><strong>2. Complex Injectable Portfolio \u2014 Prefilled Syringes, Lyophilised Products, High-Value Injectables<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p>Gland Pharma is moving beyond commodity vials into complex sterile injectables \u2014 prefilled syringes (significantly higher value per unit), lyophilised injectables (complex freeze-dried drugs), and specialty peptide injectables. This complex product mix shift commands better margins than standard commodity injectable vials.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"3_US_European_and_Australian_Market_Access_%E2%80%94_FDA_and_EMA_Approved_Facilities\"><\/span><strong>3. US, European, and Australian Market Access \u2014 FDA and EMA Approved Facilities<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p>Gland Pharma&#8217;s US FDA-approved and EMA-approved injectable manufacturing facilities enable commercial supply to the world&#8217;s highest-value pharmaceutical markets \u2014 where injectable pricing is significantly better than India&#8217;s generic domestic market.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"4_CDMO_Business_Growth_%E2%80%94_Global_Pharma_Outsourcing_Injectable_Manufacturing\"><\/span><strong>4. CDMO Business Growth \u2014 Global Pharma Outsourcing Injectable Manufacturing<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p>Gland Pharma is growing its CDMO (contract development and manufacturing) business where global pharmaceutical companies outsource injectable development and commercial manufacturing. CDMO relationships provide multi-year revenue visibility at higher margins than pure generic product competition.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"5_Complex_Sterile_Manufacturing_Scale_%E2%80%94_300-Plus_ANDA_Pipeline_in_US\"><\/span><strong>5. Complex Sterile Manufacturing Scale \u2014 300-Plus ANDA Pipeline in US<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p>Gland Pharma has 300-plus ANDA (Abbreviated New Drug Application) filings with USFDA \u2014 one of India&#8217;s largest injectable ANDA pipelines \u2014 providing a multi-year US product launch pipeline that generates generic market entry revenue sequentially.<\/p>\n<h2><span class=\"ez-toc-section\" id=\"Key_Cons_of_Gland_Pharma_Share\"><\/span><strong>Key Cons of Gland Pharma Share<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<h3><span class=\"ez-toc-section\" id=\"1_ROE_of_1267_Percent_Below_Injectable_Pharma_Quality_Benchmark\"><\/span><strong>1. ROE of 12.67 Percent Below Injectable Pharma Quality Benchmark<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p>At 12.67 percent ROE with debt-to-equity of 0.07x, Gland Pharma is below quality pharma benchmark \u2014 reflecting US generic injectable price erosion, one-time revenue recognition timing issues, and the period of product mix transition from commodity vials to complex injectables.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"2_Chinese_Parent_Fosun_Pharma_51_Percent_Stake_%E2%80%94_US_Market_Geopolitical_Risk\"><\/span><strong>2. Chinese Parent Fosun Pharma 51 Percent Stake \u2014 US Market Geopolitical Risk<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p>Gland Pharma&#8217;s majority Chinese parent Fosun Pharma creates geopolitical risk for its US pharmaceutical business. US government scrutiny of Chinese-owned pharmaceutical supply chains \u2014 including potential USFDA import restrictions or US customer preference for non-Chinese-owned suppliers \u2014 is a material business risk.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"3_US_Generic_Injectable_Price_Erosion_%E2%80%94_Competition_From_Indian_and_Chinese_Generic_Makers\"><\/span><strong>3. US Generic Injectable Price Erosion \u2014 Competition From Indian and Chinese Generic Makers<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p>US generic injectable markets face intense price erosion from multiple Indian ANDA filers (Dr. Reddy&#8217;s, Sun Pharma, Aurobindo) and Chinese generic companies. Standard injectable vial prices in the US have eroded 60 to 80 percent in competitive segments.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"4_PE_of_5839x_Expensive_for_Current_ROE_%E2%80%94_Requires_Complex_Product_Mix_Shift_to_Justify\"><\/span><strong>4. PE of 58.39x Expensive for Current ROE \u2014 Requires Complex Product Mix Shift to Justify<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p>At 58.39x PE for 12.67 percent ROE, Gland Pharma share is very expensive relative to current earnings quality. The PE is pricing in the complex injectable and CDMO revenue mix shift that will take 3 to 5 years to fully materialise in reported earnings.<\/p>\n<p style=\"margin-top: 24px;\"><a href=\"https:\/\/univest.in\/screeners\"><strong>Use the Univest Screener to Analyse Stocks for Free<\/strong><\/a><\/p>\n<h2><span class=\"ez-toc-section\" id=\"Is_Gland_Pharma_Share_a_Good_Investment_in_2026\"><\/span><strong>Is Gland Pharma Share a Good Investment in 2026?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p>Gland Pharma share is India&#8217;s largest injectable pharma investment with genuine sterile manufacturing moat. Chinese parent geopolitical risk and US generic price erosion are real structural constraints at 58x PE. Consider as a small quality injectable pharma allocation with Chinese ownership risk awareness.<\/p>\n<h2><span class=\"ez-toc-section\" id=\"Key_Risks_Before_Buying_Gland_Pharma_Share\"><\/span><strong>Key Risks Before Buying Gland Pharma Share<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<ul>\n<li>US government imposing restrictions on Fosun-owned pharmaceutical US market operations<\/li>\n<li>US generic injectable price erosion in key Gland product categories from new ANDA competition<\/li>\n<li>CDMO business ramp-up taking longer than expected keeping ROE suppressed below 15%<\/li>\n<li>USFDA warning letter on Gland&#8217;s injectable facility disrupting US supply<\/li>\n<\/ul>\n<h2><span class=\"ez-toc-section\" id=\"Conclusion\"><\/span><strong>Conclusion<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p>The Gland Pharma share offers india&#8217;s largest injectable pharmaceutical manufacturer \u2014 sterile manufacturing moat as its primary investment case. Weigh it against roe of 12.67 percent below injectable pharma quality benchmark and the risks above before investing. Use the Univest Screener and consult a SEBI-registered advisor.<\/p>\n<p style=\"margin-top: 24px;\"><em>Download the <a href=\"https:\/\/apps.apple.com\/in\/app\/univest-stock-market-research\/id1576403520\" rel=\"nofollow noopener\" target=\"_blank\">Univest iOS App<\/a> or <a href=\"https:\/\/play.google.com\/store\/apps\/details?id=com.univest.stockmarket\" rel=\"nofollow noopener\" target=\"_blank\">Univest Android App<\/a> to track Gland Pharma share price live.<\/em><\/p>\n<div style=\"background: #CC0000; border-radius: 8px; padding: 16px 20px; margin: 24px 0;\">\n<p style=\"color: #ffffff; font-size: 13px; line-height: 1.7; margin: 0;\"><strong style=\"color: #ffffff;\">Disclaimer:<\/strong> Data from publicly available sources. Approximate as of 7 Aug 2026. Verify on nseindia.com and bseindia.com. Not investment advice by Univest (SEBI RA INH000013776).<\/p>\n<\/div>\n<h2><span class=\"ez-toc-section\" id=\"Frequently_Asked_Questions_%E2%80%94_Gland_Pharma_Share\"><\/span><strong>Frequently Asked Questions \u2014 Gland Pharma Share<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<h3><span class=\"ez-toc-section\" id=\"What_are_the_main_pros_of_Gland_Pharma_share\"><\/span><strong>What are the main pros of Gland Pharma share?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p><strong>Ans.<\/strong> India&#8217;s largest injectable pharma manufacturer with sterile manufacturing moat, complex prefilled syringe and lyophilised injectable mix improving margins, US FDA and EMA approved facilities enabling high-value market access, CDMO business providing multi-year contracted revenue, and 300-plus ANDA pipeline for US sequential generic launches.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"What_are_the_risks\"><\/span><strong>What are the risks?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p><strong>Ans.<\/strong> ROE 12.67% below quality benchmark, Chinese parent Fosun 51% stake creating US market geopolitical risk, US generic injectable price erosion from competition, and PE 58.39x expensive requiring complex product mix shift to justify. Monitor Chinese ownership regulatory developments in US.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"Is_Gland_Pharma_share_a_good_investment\"><\/span><strong>Is Gland Pharma share a good investment?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p><strong>Ans.<\/strong> India&#8217;s largest injectable pharma with Chinese ownership risk at expensive PE. Consider as small quality injectable allocation with risk awareness. Consult a SEBI-registered advisor. Not investment advice.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"What_is_the_52-week_range\"><\/span><strong>What is the 52-week range?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p><strong>Ans.<\/strong> 52-week high approximately Rs 2,800, low Rs 1,600. Current Rs 2,050. Verify at nseindia.com.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"What_are_sterile_injectables_and_why_is_manufacturing_them_difficult\"><\/span><strong>What are sterile injectables and why is manufacturing them difficult?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p><strong>Ans.<\/strong> Sterile injectable pharmaceuticals (vials, ampoules, prefilled syringes) are drug solutions injected directly into the bloodstream or body tissues \u2014 requiring absolute sterility because any microbial contamination can be fatal. Manufacturing requires cleanrooms meeting ISO Class 5 or better conditions, positive pressure air filtration systems, aseptic filling equipment, and continuous environmental monitoring. FDA approval requires extensive validation of the entire manufacturing process. The difficulty of meeting these standards \u2014 requiring years of investment and regulatory audit cycles \u2014 is the primary barrier that protects Gland Pharma&#8217;s sterile injectable manufacturing from easy competitive replication.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"What_is_Fosun_Pharmas_ownership_of_Gland_Pharma\"><\/span><strong>What is Fosun Pharma&#8217;s ownership of Gland Pharma?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p><strong>Ans.<\/strong> Fosun Pharmaceutical Group (Shanghai Stock Exchange listed, a major Chinese pharmaceutical and healthcare conglomerate) holds 51.79 percent of Gland Pharma \u2014 giving it majority control. Fosun acquired this stake in 2017 when Gland was still private, making it one of the largest Chinese acquisitions of an Indian pharmaceutical company. Since Gland&#8217;s 2020 IPO, Fosun has maintained its majority stake. The geopolitical risk is that US government or US healthcare customers may preference non-Chinese-owned pharmaceutical suppliers \u2014 a risk that has not yet materialised into concrete business impact but remains a strategic uncertainty.<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Gland Pharma share pros and cons: India&#8217;s largest injectable pharma at 58.39x PE with Chinese parent Fosun ownership risk and US generic price erosion analysed for 2026.<\/p>\n","protected":false},"author":28,"featured_media":194326,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[842],"tags":[3802],"class_list":["post-194327","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-news","tag-news"],"metadata":{"rank_math_internal_links_processed":["1"],"_thumbnail_id":["194326"],"_edit_lock":["1786357034:28"],"_last_editor_used_jetpack":["block-editor"],"rank_math_primary_category":["842"],"rank_math_seo_score":["76"],"rank_math_title":["Gland Pharma Share Pros and Cons 2026 | GLAND Injectable Pharma Analysis"],"rank_math_description":["Gland Pharma share pros and cons: India's largest injectable pharma company at 58.39x PE with 12.67% ROE versus Chinese parent Fosun ownership and US generic price erosion."],"rank_math_focus_keyword":["Gland Pharma Share"],"rank_math_robots":["a:2:{i:0;s:7:\"noindex\";i:1;s:8:\"nofollow\";}"],"_edit_last":["28"],"_ez-toc-disabled":[""],"_ez-toc-insert":[""],"_ez-toc-header-label":[""],"_ez-toc-alignment":["none"],"_ez-toc-heading-levels":["a:0:{}"],"_ez-toc-alttext":[""],"_ez-toc-visibility_hide_by_default":[""],"_ez-toc-hide_counter":[""],"_ez-toc-exclude":[""],"_ez-toc-position-specific":["before"],"stm_select_gm_zoom":[""],"stm_agenda":[""],"stm_host":[""],"stm_select_approved_denied":[""],"stm_multiselect_approved":[""],"stm_multiselect_denied":[""],"stm_date":[""],"stm_time":[""],"stm_timezone":[""],"stm_duration":[""],"stm_password":[""],"stm_waiting_room":[""],"stm_join_before_host":[""],"stm_host_join_start":[""],"stm_start_after_participants":[""],"stm_mute_participants":[""],"stm_enforce_login":[""],"stm_alternative_hosts":[""],"top_bar_custom_style":[""],"top_bar_bg":[""],"wc_top_bar_cart_custom_style":[""],"wc_top_bar_cart_color":[""],"wc_top_bar_cart_icon_color_hover":[""],"wc_top_bar_cart_counter_color":[""],"wc_top_bar_cart_counter_color_hover":[""],"wc_top_bar_cart_counter_bg":[""],"wc_top_bar_cart_counter_bg_hover":[""],"top_bar_wpml_switcher_custom_style":[""],"wpml_switcher_color":[""],"top_bar_wpml_switcher_bg":[""],"top_bar_wpml_switcher_bg_hover":[""],"top_bar_wpml_switcher_color_hover":[""],"top_bar_socials_custom_style":[""],"top_bar_socials_color":[""],"top_bar_socials_color_hover":[""],"top_bar_search_custom_style":[""],"top_bar_search_color":[""],"top_bar_search_icon_color_hover":[""],"top_bar_contact_info_style":[""],"top_bar_contact_info_color":[""],"top_bar_contact_info_link_color":[""],"top_bar_contact_info_link_color_hover":[""],"top_bar_contact_info_select_bg":[""],"top_bar_contact_info_select_color":[""],"top_bar_contact_info_select_drop_bg":[""],"top_bar_contact_info_select_items_bg":[""],"top_bar_contact_info_select_items_color":[""],"top_bar_contact_info_select_items_hover":[""],"header_inverse":["default"],"enable_header_transparent":["off"],"header_nav_custom_style":[""],"header_bg":[""],"header_shadow":[""],"wc_cart_custom_style":[""],"wc_cart_icon_color":[""],"wc_cart_icon_color_hover":[""],"wc_cart_counter_color":[""],"wc_cart_counter_color_hover":[""],"wc_cart_counter_bg":[""],"wc_cart_counter_bg_hover":[""],"header_wpml_switcher_custom_style":[""],"header_wpml_switcher_color":[""],"header_wpml_switcher_color_hover":[""],"header_wpml_switcher_bg":[""],"header_wpml_switcher_bg_hover":[""],"header_socials_custom_style":[""],"header_socials_color":[""],"header_socials_color_hover":[""],"header_search_custom_style":[""],"header_search_icon_color":[""],"header_search_icon_color_hover":[""],"header_contact_info_style":[""],"header_contact_info_color":[""],"header_contact_info_link_color":[""],"header_contact_info_link_color_hover":[""],"header_button_custom_style":[""],"header_button_color":[""],"header_button_color_hover":[""],"header_button_bg":[""],"header_button_bg_hover":[""],"header_nav_menu_customize":[""],"header_nav_menu_link_color":[""],"header_nav_menu_link_color_hover":[""],"header_nav_menu_link_color_active":[""],"header_nav_menu_link_arrow_color":[""],"header_nav_menu_link_arrow_color_hover":[""],"header_nav_menu_level_1_bg":[""],"header_nav_menu_level_1_link_color":[""],"header_nav_menu_level_1_link_color_hover":[""],"header_nav_menu_level_1_link_bg_hover":[""],"header_nav_menu_level_1_link_arrow_color":[""],"header_nav_menu_level_1_link_arrow_color_hover":[""],"header_nav_menu_level_2_bg":[""],"header_nav_menu_level_2_link_color":[""],"header_nav_menu_level_2_link_color_hover":[""],"header_nav_menu_level_2_link_bg_hover":[""],"header_mega_menu_bg":[""],"header_mega_menu_title_color":[""],"header_mega_menu_title_color_hover":[""],"header_mega_menu_description_color":[""],"header_mega_menu_description_link_color":[""],"header_mega_menu_description_link_color_hover":[""],"header_mega_menu_color":[""],"header_mega_menu_color_hover":[""],"header_mega_menu_border_color":[""],"header_mega_menu_icons_color":[""],"header_nav_menu_customize_end":[""],"hfe_enabled_notice":[""],"disable_title_box":["default"],"hfe_disabled":[""],"enable_transparent":["default"],"title_box_title_bg_color":[""],"title_box_bg_custom_image":["default"],"title_box_bg_image":[""],"title_box_bg_position":["default"],"metabox_title_box_bg_position_x":[""],"metabox_title_box_bg_position_y":[""],"metabox_title_box_bg_attachment":["default"],"title_box_bg_size":["default"],"metabox_title_box_bg_size_slider":[""],"title_box_bg_repeat":["default"],"disable_title":["default"],"title_box_title_color":[""],"title_box_title_line_color":[""],"disable_breadcrumbs":["default"],"metabox_title_box_breadcrumbs_color":[""],"metabox_title_box_links_color":[""],"metabox_title_box_links_color_hover":[""],"content_bg_transparent":[""],"show_popup_single":[""],"popups_single":[""],"popups_single_event":[""],"popup_single_event_open_delay":[""],"popup_single_event_showing_in":[""],"popup_single_event_date_from":[""],"popup_single_event_date_to":[""],"popup_single_event_time_from":[""],"popup_single_event_time_to":[""],"popup_single_animation":[""],"popup_single_responsive":[""],"separator_footer_copyright_border_t":[""],"name":[""],"email":[""],"phone":[""],"company":[""],"memberId":[""],"testimonial_position":[""],"testimonial_company":[""],"testimonial_bg_img":[""],"testimonial_video_url":[""],"popups_width":[""],"popups_height":[""],"popups_image_bg":[""],"popups_color_bg":[""],"popups_border_radius":[""],"popups_template":[""],"rank_math_analytic_object_id":["35522"]},"jetpack_sharing_enabled":true,"jetpack_featured_media_url":"https:\/\/univest.in\/blogs-2\/wp-content\/uploads\/2026\/08\/pros-cons-investing-gland-share.png","_links":{"self":[{"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/posts\/194327","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/users\/28"}],"replies":[{"embeddable":true,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/comments?post=194327"}],"version-history":[{"count":1,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/posts\/194327\/revisions"}],"predecessor-version":[{"id":194579,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/posts\/194327\/revisions\/194579"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/media\/194326"}],"wp:attachment":[{"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/media?parent=194327"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/categories?post=194327"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/tags?post=194327"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}